Swiss Primary Biliary Cholangitis Cohort

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The cohort enrolls adults diagnosed with PBC and plans an initial visit plus at least one annual follow-up to collect clinical data and medical history. Whole blood is taken once a year for a centralized biobank and, when available from routine care, liver tissue samples may be included. Existing medical records and coded data are also used to build high-quality prospective datasets on epidemiology, natural history, treatment response and outcomes. The platform is intended to support future scientific projects and collaborations with international PBC reference networks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases).
* Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included
* Patients/subjects aged at least 18 years and living in Switzerland are included

Exclusion Criteria:

* N/A

Where it's running

• Fondazione Epatocentro Ticino
  Lugano, Canton Ticino, Switzerland Recruiting
• Gastroenterologie und Hepatologie, Clarunis - Universitäres Bauchzentrum Basel
  Basel, Switzerland Recruiting
• Inselspital
  Bern, Switzerland Recruiting
• Spital Bülach
  Bülach, Switzerland Recruiting
• Kantonsspital Graubünden
  Chur, Switzerland Recruiting
• Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
  Geneva, Switzerland Recruiting

Study contacts

• Study coordinator: Andreas Cerny, Prof. Dr. med
• Email: andreas.cerny@hin.ch
• Phone: +41919106570

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Seladelpar and Cilofexor in Primary Biliary Cholangitis (PBC)

  This study tests whether combining seladelpar with cilofexor helps people with primary biliary cholangitis more than seladelpar alone or placebo.

  Recruiting at 4 sites Phase 2 Gilead Sciences · Colorado Springs, Colorado and 3 other locations · NCT07841977

• Austrian PBC Registry

  This registry follows adults with primary biliary cholangitis in Austrian centers to see how the disease develops over time and how biomarkers relate to complications and symptoms.

  Recruiting Medical University of Vienna · Klagenfurt, Carinthia and 10 other locations · NCT07598669

• Biochemical response and health outcomes in people with primary biliary cholangitis

  We will follow adults with primary biliary cholangitis who are taking ursodeoxycholic acid (UDCA) to see if their alkaline phosphatase levels after treatment predict how long they stay free of complications.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07449793

• Saroglitazar Magnesium for PBC with incomplete UDCA response or intolerance

  This study tests whether Saroglitazar Magnesium can help people with primary biliary cholangitis who still have high alkaline phosphatase despite UDCA or cannot take UDCA.

  Recruiting Phase 3 Zydus Therapeutics Inc. · Lakewood Rch, Florida · NCT07424677

• CS0159 for primary biliary cholangitis when UDCA doesn't work or isn't tolerated.

  This test tries to see if taking CS0159 once daily helps adults with primary biliary cholangitis who have an inadequate response to or cannot tolerate UDCA.

  Recruiting at 39 sites Phase 3 Cascade Pharmaceuticals, Inc · Hefei, Anhui and 41 other locations · NCT07282353

• Saroglitazar Magnesium-V as add-on therapy for primary biliary cholangitis

  This trial tests whether Saroglitazar Magnesium-V, compared with placebo, can improve long-term clinical outcomes in adults with primary biliary cholangitis who are on UDCA.

  Recruiting at 3 sites Phase 3 Zydus Therapeutics Inc. · Marietta, Georgia and 2 other locations · NCT07216235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.